INTRODUcTION
he use of hospital mortality rates as indicators of the quality of hospital f h l This article reports on a preliminary analysis of in-hospital mortality data and [ 
I] Infectious Diseases
identifies the data needed to produce more valid and reliable versions of these indicators.
The mortality outcomes of hospitals or clinical services are influenced by many '
Notifications
factors other than the quality of medical care. These include the patients age, sex, clinical condition, illness severity, co-morbidity, treatment received before hospitalisation, hospital admission and discharge policies, and the type or role of the hospital. Adjustment for such factors is necessary before meaningfhl comparisons of mortality rates can be made among hospitals or across time for a given hospital. Information on many of these factors is not available from routine data systems.
As a first step in developing indicators of hospital-related mortality we examined deaths occurring in NSW hospitals over the past five years, focusing on the numbers and rates of in-hospital deaths, case-fatality rates {CF'Rs) for selected conditions, and variations iii all-causes mortality witliiii different categories of hospital. Only crude rates are presented here -there has been no attempt to adjust for even basic influences such as casemix, age and sex. The results of basic risk-adjusted analyses using available data will be reported in the near future. Our intention is to determine whether existing data will allow for the development of appropriate indicators or whether additional information is required.
METHODS
We analysed data on separations from all public and private hospitals in NSW over the five consecutive financial years between 1988-89 and 1992-93. The data source was the NSW Inpatient Statistics Collection. Analyses were based on the principal diagnosis or procedure, which was coded according to the International
COiTespondeflce Classification of Diseases and Causes of Death, 9th Revision, Clinical Modificotion
(ICD-9 CM). The following conditions or procedures were selected for review:
Please address all
• I acute myocardial infarction (AMI) (ICD-9CM code N410); I correspondence and potential contributions to:
• cerebrovascular accident (CVA) (430-438);
• I aortic aneurysm (441);
The Edito,;
• I head injury (800, 801, 803, 804, 850-854);
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• I hip fracture (820); and The average CFR within acute hospital role groups ranged from 2 to 3 per cent over the five-year period (Table 3 ). In contrast, much higher rates were reported for other hospital groups such as public nursing homes (17 per cent) and public subacute hospitals (19 per cent) which included hospices and rehabilitation centres. Figure 1 depicts the variability of CFRs among public hospitals in 1992-93, displaying the median and inter-quartile range for each type of hospital. In the same year, the CFR in principal referral hospitals ranged from 1.0 per cent to 3.5 per cent, while for major rural base hospitals the range was between 1.8 per cent and 2.8 per cent, and for public hospitals it was from 0.4 per cent to 11.5 per cent. 
DISCUSSION
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n NSW in 1991 colorectal cancer was the second most common cancer affecting women and men, after breast and prostate cancer, respectively. Because of the burden of this disease and because prevention is not possible, populationbased screening to detect and remove colorectal adenomas and early asymptomatic cancers has been advocated by some2. However, the decision to implement population-based screening is a comp]ex one. Early detection and treatment of colorectal neoplasms (adenomas and cancers) must be shown to be effective in reducing disease mortality and any benefits of screening must outweigh potential morbidity caused. Other considerations include the feasibility, cost and acceptability of screening to Australians and the likelihood of patient and physician compliance with a screening program. We examined the evidence about the effectiveness of screening and related issues to inform screening policy. This included a comprehensive and critical review of the literature, preliminary economic analysis of screening in the Australian health care setting and correspondence with Australian investigators for information about local research relevant to screening. A summary of this review and its recommendations are presented below and in Table 4 . The full report, including the tabulated results of the critical appraisal of the literature, is available from the Epidemiology and Health Services Evaluation Branch.
Is SCREENING EFFECTIVE?
Whether screening is effective is the first and crucial question to ask before embarking on a screening program. Randomised controlled trials provide the best quality evidence about screening effectiveness. There are five large trials (one non-randomised) investigating the effectiveness of screening using the faecal occult blood test (FOBT) Hemoccult'°'°'''°''". The New York trial'20 is evaluating Hemoccult additional to sigmoidoscopy which was offered to all study participants. The major characteristics and mortality findings of the trials are given in Table 5 . In all trials, 1-Jemoccult positive subjects were referred for further investigation which was mainly colonoscopy, or alternatively, sigmoidoscopy with double contrast barium enema. Colorectal neoplasms detected were removed.
Three of the trials have reported mortality findings, analysed by intention to treat'1'. Only the Minnesota trial' has reported a statistically significant 33 per cent reduction in colorectal cancer mortality with annual screening (Table  5 )-However, the findings of the Minnesota trial must be viewed with caution for several reasons. There are inconsistencies in the numbers of colorectal cancers
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While our development of risk-adjusted indicators is still at an early stage, there are a few excellent examples of clinical groups in NSW that have produced and implemented such indicators to monitor the quality of their services. One such example is the Australian and New Zealand Intensive Care Society (AINZICS). ANZICS, partially funded by the NSW Health Department's Health Outcomes Program, is installing a standard clinical information system in intensive care units throughout Australia to provide riskadjusted mortality data to the participating units. The information from this system will allow individual units to compare their overall performance and condition-specific mortality to an international benchmark and facilitate monitoring of trends in performance. The development of such systems is complementary to the work being carried out in the Epidemiology and Health Services Evaluation Branch.
The next steps in our exploration of hospital mortality will be to:
•recalculate in-hospital mortality rates adjusting for age, sex and casemix, and condition-specific mortality rates adjusting for age and sex; • evaluate methods for using existing inpatient data in the measurement of co-morbidity and severity of illness and in risk adjustment; compare the use of routinely reported inpatient data and these algorithms against results derived from more comprehensive clinical databases, e.g. Trauma Registries; demonstrate the feasibility and usefulness of linking routinely reported inpatient data to mortality data to extend this analysis to include post-discharge deaths; and assess the usefulness of additional data items from existing hospital information systems and processes which may be of value in the measurement of ccmorbidity, severity of illness and risk adjustment. This evaluation will determine whether suitable data items are captured by hospital records, the extent and consistency of recording across institutions and the feasibility of computerisation.
This work will be assisted by a grant from the Commonwealth Government and will include collaboration with the Victorian Department of Health and Community Services.
SUMMARY OF REVIEW AND RECOMMENDATIONS ABOUT COLORECAL CANCER SCREENING
1. Population screening is not recommended as screening effectiveness has not yet been adequately established. Follow-up continues in the major trials and review of this position will be necessary in a few years time when further information is available. 2. Although evidence for screening persons at high risk, such as those with a known genetic susceptibility for colorectal cancer, is also lacking, it seems prudent to screen such groups on the basis of the increased risk.
3. Further work is needed in Australia to determine the implications of introducing screening for health services planning and costs, to determine the most accurate and feasible screening test and the likely compliance of Australians with screening, and to determine and cater for the psychosocial consequences of screening.
reported, information about vital status for all study participants at follow-up is not given, there is no intennediate biennial screening benefit and about one-third of all people screened had colonoscopy with its attendant risks and costs. It is possible that using colonoscopy alone on a random sample of one-third of people from either group would have resulted in this mortality reduction.
The New York trial" has reported a borderline significant 43 per cent reduction in colorectal cancer mortality with annual screening in one of the subgroups examined (Table  5) . But the New York trial was a non-randomised study and study groups were demonstrably not comparable, suggesting bias in the allocation of subjects to study groups. The Danish trial" has reported a non-significant 17 per cent reduction in colorectal cancer mortality with biennial screening (Table 5) . Follow-up continues in four of the five trials. In the interim, evidence for the effectiveness of screening using Hemoccult remains inconclusive.
Screening using flexible sigmoidoscopy has been suggested2. The only evidence about screening effectiveness using sigrnoidoscopy comes from two recent case-control studies'4". The authors reported 60-80 per cent reductions in colorectal cancer mortality with sigmoidoscopic screening but these results must be interpreted cautiously because of the biases inherent in case-control studies to evaluate screening. In addition, sigmoidoscopy is more invasive and expensive than Hemoccult and has an estimated rate of bowel perforation of 0.02 per cent'6. Randomised trials evaluating the effectiveness of screening using sigrnoidoscopy are under way irs the United Kingdom'7 and the United States". There are no studies investigating the effectiveness of screening using colonoscopy. However, colonoscopy is probably unsuitable as a screening test as it is expensive, invasive, requires sedation and bowel preparation and has an estimated complication rate of perforation, haemorrhage and death of 0.17 per cent, 0.03 per cent and 0.02 per cent respectively.
FAECAL OCCULT BLOOD TESTS (FOBTS)
The major trials are evaluating screening using Hemoccult, an inexpensive guaiac-based FOBT which detects blood products in faeces. 
WOULD AUSTRALIANS PARTICIPATE IN SCREENING?
Assuming that colorectal cancer screening is effective, compliance of the Australian population with screening would be critical to the ability of a screening program to reduce mortality rates. The notion of compliance is complex, encompassing initial and continued participation in screening and adherence to follow-up, treatment recommendations and post-treatment surveillance.
Compliance of screen-positive people with follow-up investigations is essential to maximise the effectiveness of screening. Compliance with follow-up was high in the major trials (77-93 per cent). However, the numbers of eligible people who choose to participate in screening will influence the public health impact of the screening program in its ability to reduce colorectal cancer mortality. Compliance with initial Hemoccult testing ranged from 53 per cent to 80 per cent in the major trials (Table 5 ) and was positively associated with younger age and female gender. Compliance with rescreening, where offered to all those in the screen group, not just previous compliers, was lower (20-58 per cent, Table 5 ). Personalised invitations to screening, reminder letters or telephone calls increased compliance in the trials and other studies"". Preliminary Australian research on compliance with colorectal cancer screening has been done"7" but more work is needed to assess barriers to screening participation and to test strategies for overcoming these barriers.
PSYCHOSOCIAL IMPACT OF SCREENING
In the major trials, screening with Hemoccult resulted in a positive predictive value for cancer ranging from 2 per cent to 18 per cent and 2 to 4 per cent if Hemoccult slides were rehydrated (Table 5) . Therefore, more than 80 per cent of positives are false positives: such large numbers of people receiving falsely positive results is important since a positive result is not unexpectedly associated with distress'1". All these people would require colonoscopy, an invasive procedure which, in addition to the physical risk, may cause pain and embarrassment' and significant anxiety'. There is also evidence from other screening programs that anxiety aroused by a false positive result
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Continued from page 29 may be long term32 and negative results may reassure people who then do not seek medical care for rectal bleeding20. Implementation of screening requires attention to the provision of appropriate information about its pm-pose and pitfalls. There also need to be support services for people receiving, and undergoing investigation for, positive test results.
ECONOMIC CONSIDERATIONS
The risks, benefits and costs are major factors in decisions about screening. Information on screening benefits in terms of survival with and without the disease remains unclear without conclusive randomised trial evidence but assumptions about survival, the natural history of the disease, the screening procedures and clinical history can be made to compare the costs and benefits of screening. In the US, Eddy33 has evaluated three screening strategies which resemble proposed Australian screening guidelinesz2O: annual FOBT, annual FOBT plus sigmoidoscopy every five years and annual FOBT plus colonoscopy every five years. The estimated cost-effectiveness ratio for each strategy was $US8,800, $IJS7,760 and $US2O,700 per life year gained respectively. However, based on the findings of the Minnesota trial, the cost-effectiveness of FOBT screening may be considerably tmderestimated. We have begun preliminary estimates of the cost-effectiveness of screening in an Australian context using Australian cancer incidence data and Australian health care costs. The results of this analysis will be reported when available.
CONCLUSION AND RECOMMENDATIONS
Contrary to the recommendations of The Gut Foundation2, we recommend that screening for colorectal cancer should not be implemented on a population basis as there is not sufficient evidence of its effectiveness. This position will need review when further trial evidence becomes available. Screening for groups at high risk of colorectal cancer such as those with a known genetic predisposition seems prudent on the basis of the increased risk. If evidence accruing from the trials over the next few years warrants a decision to screen, it must be with the support of general practitioners, with quality control for FOBTs and with adequate linkage to ensure appropriate management and follow-up of people with positive results23. In addition, there must be monitoring and evaluatioll of the screening program's ability to detect early cancers and minimise the interval cancer rate. In the interim, further investigation in the areas of compliance, psychosocial impact and better screening tests, as well as more detailed economic evaluation, is needed. 
ProvisIonal
HA EMOPHIL US INFLUENZAE TYPE B
The first notification in five months for fib in a child under one year old has been received by the Central Coast Public Health Unit. The six-month-old child has been discharged from Gosford Hospital. The infant received a single dose of Hibtiter at the age of three months but did not receive routine boosters, as recommended.
The immunisation program against Haemophilus influenzae type B, introduced in July 1993, is already demonstrating excellent effect on the epidemiology of this infection. No notifications for Haemophilus infloenzae type b have been received for the past three months for infants. Only three notifications were received for Januai'y, for a rate of 0.6/100,000 population. This compares with a notification rate of 2.0 per 100,000 population for January 1993. The mean age for notifications was 8.0 years (range four months to 36 years). Fifteen per cent of notifications were for neonates and infants ( one year of age). Fifty-nine per cent of notifications were for children over the age of five years, while 24 per cent were for people 12 years and older.
MEASLES
From July 1 this year, it is anticipated that the schoolgirl rubella program will be replaced by a universal schoolchild measles-mumps-rubella program.
PERTUSSIS (WHOOPING COUGH)
The pertussis notification rate for the State for 1994 is 16. 1/100,000 population. This compares with a rate of 24.6 for 1993.
Eighteen per cent of notifications were for children under five years of age. A further 43 per cent of notifications were for school-aged children.
North Coast Public Health Unit (PHIl) has received 74 notifications at a rate of 116.8/100,000 population. The PHIl has investigated all cases and advised contacts of appropriate measures to minimise risk of further spread of infection. Media releases have been made in community newspapers, and liaison between the PHU and the local Divisions of General Practice will promote the use of triple antigen.
FOODBORNE ILLNESS
A case of Salmonella enteritidis phage type 4 has been notified to Epidemiology Branch by the Microbiological Diagnostic Unit, University of Melbourne, which administers the National Salmonella Surveillance Scheme. 
cramps, headaches and vomiting. The investigation has not concluded, but untreated river water used for swimming, drinking purposes and food preparation is suspected as the vehicle of transmission of the infectious agent.
NON-NOTIFIABLE STD SURVEILLANCE
Lymphogranuloma venereum (LGV) is caused by infection of lymphatic tissue by particular strains of Chiamydia trachoinatis. It is endemic to some countries of Africa, South America, South-East Asia, and India.
LGV is usually diagnosed more frequently in men, as infection is more likely to be asymptomatic in women. It has been diagnosed only sporadically in Europe, North America and Australia. Sentinel surveillance indicates that these C. trachomatis strains are still extremely rare in NSW. Male   --------------venereum  Female   --------------Total   --------------- 
